PDB41 - Health Utility Scores in Patients With Type 2 Diabetes Mellitus in Indonesia

Abstract

Pharmacoeconomics analysis, especially cost-utility analysis, requires health utility score based on severity, which is used to calculate Quality Adjusted Life Years. The purpose of this study was to determine utility scores based on complications, comorbid, and therapeutic regimens in patients with type 2 diabetes mellitus. The study design was cross sectional in patients with type 2 diabetes mellitus who visited the secondary health service center in Yogyakarta, Indonesia from July to December 2017. The EQ-5D-5L questionnaire was used to measure utility. The value set developed for the Indonesian population is used for health utility scoring. Differences in utility scores based on characteristics, complications, comorbids, and therapy were tested using independent t tests to compare 2 categories and ANOVA if more than 2 categories. Results of the study of 400 diabetes mellitus patients, mean age 60.74 (8.61) years, showed utility scores and mean VAS values of 0.74 (0.22) and 74.60 (12,23). Problems related to mobility were reported by 42.67% of patients, while for self-care domain 11%, daily activity 48%, pain/discomfort 76.33% and anxiety/depression by 44.33%. There were significant differences in utility scores in the complication category, where the utility of diabetes mellitus patients without complications was 0.79 (0.16), with microvascular complications of 0.76 (0.19), macrovascular 0.71 (0.19), and micro-and macrovascular complications of 0.59 (0.31). Patients with stroke showed the lowest utility score, ie 0.43 (0.32). Differences in therapeutic regimens given also indicate different utility scores. Health utility scores in patients with diabetes mellitus with complications lower than without complications. Health utility scores based on patient health status can be used as supporting data in pharmacoeconomic analysis.